NOT-HL-20-780: NHLBI Announces Availability of Frequently Asked Questions (FAQs) for RFA-HL-21-009, Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for RFA-HL-21-009, Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)

Notice Number: NOT-HL-20-780

Key Dates
Release Date: April 8, 2020

Related Announcements
RFA-HL-21-009

Issued by
National Heart, Lung, and Blood Institute (NHLBI

Purpose

The purpose of this Notice is to inform potential applicants that NHLBI has posted a set of responses to Frequently Asked Questions (FAQs) regarding RFA-HL-21-009 "Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)". The FAQs are available on the NHLBI website at the following link: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/all-funding-opportunity-announcements-3120.

Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.

Inquiries

Please direct all inquiries to:

Shimian Zou, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8301
Email: [email protected]